Analysts’ Viewpoint
The global lung cancer treatment market is expected to grow significantly in the next few years owing to the increase in incidence of lung cancer and development of novel therapies and technologies. High mortality rate associated with lung cancer is likely to propel the demand for new and effective treatments such as lung lesion treatment. Furthermore, increase in adoption of targeted therapies and immunotherapies is anticipated to accelerate market expansion.
Development of new technologies such as liquid biopsy, which can detect lung cancer at an early stage, is offering lucrative opportunities to market players. Pharmaceutical companies and government organizations are investing significantly in R&D of innovative products. However, high cost of treatment and limited availability of healthcare resources in some regions are projected to hamper market growth.
Lung cancer is one of the most common types of metastatic cancer globally. It is the leading cause of cancer-related deaths. It is a malignant tumor that starts in the lung tissue and could spread to other parts of the body through the bloodstream or lymphatic system. Non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) are the most common types of lung cancer.
The treatment of lung cancer depends on the stage and type of cancer, as well as the overall health of a patient. Primary treatment options for lung cancer include surgery, lung cancer therapy such as radiation therapy, and chemotherapy.
Targeted therapy and immunotherapy have become popular treatment options for lung cancer in the past few years. It is a type of treatment that targets specific molecules involved in the growth and spread of lung cancer. On the other hand, it helps the immune system fight cancer cells.
Surgery is typically the first choice of treatment for early-stage lung cancer and is used to remove the tumor and a margin of healthy tissue around it. Radiation therapy uses high-energy X-rays to destroy cancer cells, while chemotherapy uses drugs to kill cancer cells. Both radiation therapy and chemotherapy could be used alone or in combination with surgery. Treatment for advanced lung cancer typically involves a combination of chemotherapy and targeted therapy. Immunotherapy is also an option for some patients with advanced lung cancer.
Alternative and complementary therapies are also available for lung cancer patients. These include herbal supplements, acupuncture, and massage therapy, which could help alleviate symptoms and improve the patient's quality of life.
The COVID-19 pandemic has had a significant impact on the global market for lung cancer treatment, with several positive developments regarding new and innovative treatments. The global lung cancer treatment industry has been driven by digital health solutions in the past few years.
The pandemic has resulted in an increase in the adoption of digital health solutions such as telemedicine, which enables remote consultation and monitoring of lung cancer patients. This has led to an increase in lung cancer treatment market demand for digital health solutions, as more patients are able to receive medical attention remotely, and doctors are able to monitor patients more closely.
The pandemic has also led to a shift toward personalized medicine, which involves the usage of genetic information to tailor treatment to the specific needs of individual patients. The need for precise treatment options that target specific genetic mutations becomes more important in the fight against the disease. This is boosting the demand for precision medicine solutions for lung cancer.
Growth in the prevalence of lung cancer is expected to drive the demand for new and effective lung cancer treatments. The aging population and the rise in the prevalence of risk factors such as smoking and air pollution are likely to increase the number of cases of lung cancer.
According to the International Association for the Study of Lung Cancer, lung cancer is the most common cancer in some countries, accounting for about 30% of all cancer cases. Around 2.2 million new cases and 1.8 million lung cancer deaths were reported across the globe in 2020. The incidence of lung cancer is projected to rise in the next few years.
The development of new and effective treatments is a key driver of the global lung cancer treatment market. There has been a shift toward targeted therapies and immunotherapies, which have been shown to improve patient outcomes and have fewer side effects compared to traditional chemotherapy.
Targeted therapies, such as tyrosine kinase inhibitors (TKIs) and monoclonal antibodies (mAbs), are designed to target specific molecules that are involved in the growth and spread of cancer cells. These therapies have been proven to be effective in treating non-small cell lung cancer (NSCLC), and have become a standard of care for some patients with advanced NSCLC.
The development of new technologies such as liquid biopsy, which can detect lung cancer at an early stage, is expected to drive market development. These technologies are less invasive and provide a more accurate diagnosis of lung cancer, which can improve patient outcomes.
In terms of cancer type, the NSCLC segment accounted for the largest global lung cancer treatment market share in 2021. NSCLC is the most common type of lung cancer and accounts for about 85% of all lung cancer cases. It has several subtypes, including adenocarcinoma, squamous cell carcinoma, and large cell carcinoma. Several treatment options, such as surgery, radiation therapy, chemotherapy, targeted therapy, and immunotherapy, are available for NSCLC.
The small cell lung cancer (SCLC) segment held a 15.0% share in 2021. SCLC is characterized by rapid growth and early spread of cancer cells. It is a more aggressive form of lung cancer and is typically treated with a combination of chemotherapy and radiation therapy. The market for SCLC treatment is smaller than that for NSCLC; however, it is still a significant segment of the industry.
Based on treatment type, the targeted therapy segment dominated the global market in 2021. Targeted therapy has gained popularity as a treatment for lung cancer, especially non-small cell lung cancer (NSCLC), in the past few years.
It is a type of treatment that targets specific molecules involved in the growth and spread of cancer cells, unlike traditional chemotherapy which targets all rapidly dividing cells. This makes targeted therapy more specific and less toxic to patients.
Targeted therapy has become a standard of care for some patients with advanced NSCLC. Drugs such as tyrosine kinase inhibitors (TKIs) and monoclonal antibodies (mAbs) are examples of targeted therapies that have been approved for the treatment of lung cancer. TKIs are drugs that target specific genetic mutations that are present in certain types of lung cancer, such as EGFR mutations and ALK rearrangements, while mAbs are drugs that target specific proteins on the surface of cancer cells. These therapies have proven to be effective in treating NSCLC and have led to improved patient outcomes.
In terms of end-user, the hospital's segment held a significant share of the global lung cancer treatment business in 2021. Hospitals offer a wide range of treatment options for lung cancer patients, including surgery, radiation therapy, chemotherapy, targeted therapy, and immunotherapy. They also possess the necessary infrastructure and resources to provide comprehensive cancer care, including multidisciplinary teams of specialists who work together to provide the best possible care for patients.
Hospitals have the capacity to treat patients with advanced lung cancer, as well as those who require palliative care. Additionally, hospitals have the ability to conduct clinical trials and research, which could lead to the development of new treatments and therapies for lung cancer. This is important, as lung cancer is a complex disease and new treatments are needed to improve patient outcomes. It also allows for hospitals to offer the latest and innovative treatment options for lung cancer patients.
Cancer & radiation therapy centers and specialty clinics have a limited range of treatment options and resources compared to hospitals. These centers have less experience and expertise in treating advanced cases of lung cancer.
North America is expected to account for the largest market share during the forecast period. This can be ascribed to the presence of a large patient population and well-established healthcare infrastructure. According to the American Cancer Society, around 228,820 new cases of lung cancer and 135,720 deaths were reported in the U.S. in 2020.
Europe is also a significant market for lung cancer treatment due to the presence of a large patient population and the availability of advanced treatment options. According to the European Lung Cancer Working Party, lung cancer cases in the region were estimated at 446,000 in 2020, and 405,000 lung cancer deaths were reported in the same year.
Asia Pacific is expected to be the fastest-growing market for lung cancer treatment in the next few years. This can be ascribed to the increase in incidence of lung cancer, a surge in the geriatric population, and rise in the adoption of targeted therapies and immunotherapies. According to the International Association for the Study of Lung Cancer, lung cancer is the most common cancer in China, accounting for about 30% of all cancer cases.
The lung cancer treatment market report includes vital information about the key lung cancer drug manufacturers operating in the industry. Companies are focusing on strategies such as product launches, divestitures, mergers & acquisitions (M&A), and partnerships to strengthen their position in the market.
Pfizer, AstraZeneca, Merck (MSD), Bristol-Myers Squibb, Eli Lilly and Company, Boehringer Ingelheim, Novartis, Merck KGaA (EMD Serono), AbbVie, Takeda, Astellas Pharma, F. Hoffmann-La Roche, GlaxoSmithKline, Johnson & Johnson, Sanofi, and Amgen are the prominent players operating in the market.
Each of these players has been profiled in the report based on parameters such as company overview, financial overview, strategies, portfolio, segments, and recent developments.
|
Attribute |
Detail |
|
Size in 2021 |
US$ 39.6 Bn |
|
Forecast (Value) in 2031 |
More than US$ 102.0 Bn |
|
Compound Annual Growth Rate (CAGR) |
9.8% |
|
Forecast Period |
2022–2031 |
|
Historical Data Available for |
2017–2021 |
|
Quantitative Units |
US$ Bn for Value |
|
Market Analysis |
It includes segment analysis as well as regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, and parent industry overview. |
|
Competition Landscape |
|
|
Format |
Electronic (PDF) + Excel |
|
Segmentation |
|
|
Regions Covered |
|
|
Countries Covered |
|
|
Companies Profiled |
|
|
Customization Scope |
Available upon request |
|
Pricing |
Available upon request |
The industry was valued at US$ 39.6 Bn in 2021.
It is projected to reach more than US$ 102.0 Bn by 2031.
The CAGR is anticipated to be 9.8% from 2022 to 2031.
Increase in incidence of lung cancer and development of new & effective treatments.
The hospitals segment held the largest share in 2021.
North America is expected to account for significant share during the forecast period.
Pfizer, AstraZeneca, Merck (MSD), Bristol-Myers Squibb, Eli Lilly and Company, Boehringer Ingelheim, Novartis, Merck KGaA (EMD Serono), AbbVie, Takeda, Astellas Pharma, F. Hoffmann-La Roche, GlaxoSmithKline, Johnson & Johnson, Sanofi, and Amgen.
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Lung Cancer Treatment Market
4. Market Overview
4.1. Introduction
4.1.1. Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Lung Cancer Treatment Market Analysis and Forecast, 2017–2031
4.4.1. Market Revenue Projections (US$ Mn)
4.5. Porter’s Five Forces Analysis
5. Key Insights
5.1. Lung Cancer Epidemiology
5.2. Pipeline Analysis
5.3. Key Mergers & Acquisitions
5.4. COVID-19 Pandemic Impact on Industry (value chain and short/mid/long term impact)
6. Global Lung Cancer Treatment Market Analysis and Forecast, by Cancer Type
6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Cancer Type, 2017–2031
6.3.1. NSCLC
6.3.2. SCLC
6.4. Market Attractiveness Analysis, by Cancer Type
7. Global Lung Cancer Treatment Market Analysis and Forecast, by Treatment Type
7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Treatment Type, 2017–2031
7.3.1. Surgery
7.3.2. Radiation Therapy
7.3.3. Targeted Therapy
7.3.4. Immunotherapy
7.3.5. Chemotherapy
7.3.6. Others (palliative care)
7.4. Market Attractiveness Analysis, by Treatment Type
8. Global Lung Cancer Treatment Market Analysis and Forecast, by End-user
8.1. Introduction & Definition
8.2. Key Findings/Developments
8.3. Market Value Forecast, by End-user, 2017–2031
8.3.1. Hospitals
8.3.2. Cancer & Radiation Therapy Centers
8.3.3. Others (specialty clinics)
8.4. Market Attractiveness Analysis, by End-user
9. Global Lung Cancer Treatment Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Market Value Forecast, by Region, 2017–2031
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness Analysis, by Region
10. North America Lung Cancer Treatment Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by Cancer Type, 2017–2031
10.2.1. NSCLC
10.2.2. SCLC
10.3. Market Value Forecast, by Treatment Type, 2017–2031
10.3.1. Surgery
10.3.2. Radiation Therapy
10.3.3. Targeted Therapy
10.3.4. Immunotherapy
10.3.5. Chemotherapy
10.3.6. Others (palliative care)
10.4. Market Value Forecast, by End-user, 2017–2031
10.4.1. Hospitals
10.4.2. Cancer & Radiation Therapy Centers
10.4.3. Others (specialty clinics)
10.5. Market Value Forecast, by Country, 2017–2031
10.5.1. U.S.
10.5.2. Canada
10.6. Market Attractiveness Analysis
10.6.1. By Cancer Type
10.6.2. By Treatment Type
10.6.3. By End-user
10.6.4. By Country
11. Europe Lung Cancer Treatment Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Cancer Type, 2017–2031
11.2.1. NSCLC
11.2.2. SCLC
11.3. Market Value Forecast, by Treatment Type, 2017–2031
11.3.1. Surgery
11.3.2. Radiation Therapy
11.3.3. Targeted Therapy
11.3.4. Immunotherapy
11.3.5. Chemotherapy
11.3.6. Others (palliative care)
11.4. Market Value Forecast, by End-user, 2017–2031
11.4.1. Hospitals
11.4.2. Cancer & Radiation Therapy Centers
11.4.3. Others (specialty clinics)
11.5. Market Value Forecast, by Country/Sub-region, 2017–2031
11.5.1. Germany
11.5.2. U.K.
11.5.3. France
11.5.4. Italy
11.5.5. Spain
11.5.6. Rest of Europe
11.6. Market Attractiveness Analysis
11.6.1. By Cancer Type
11.6.2. By Treatment Type
11.6.3. By End-user
11.6.4. By Country/Sub-region
12. Asia Pacific Lung Cancer Treatment Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Cancer Type, 2017–2031
12.2.1. NSCLC
12.2.2. SCLC
12.3. Market Value Forecast, by Treatment Type, 2017–2031
12.3.1. Surgery
12.3.2. Radiation Therapy
12.3.3. Targeted Therapy
12.3.4. Immunotherapy
12.3.5. Chemotherapy
12.3.6. Others (palliative care)
12.4. Market Value Forecast, by End-user, 2017–2031
12.4.1. Hospitals
12.4.2. Cancer & Radiation Therapy Centers
12.4.3. Others (specialty clinics)
12.5. Market Value Forecast, by Country/Sub-region, 2017–2031
12.5.1. China
12.5.2. Japan
12.5.3. India
12.5.4. Australia & New Zealand
12.5.5. Rest of Asia Pacific
12.6. Market Attractiveness Analysis
12.6.1. By Cancer Type
12.6.2. By Treatment Type
12.6.3. By End-user
12.6.4. By Country/Sub-region
13. Latin America Lung Cancer Treatment Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Cancer Type, 2017–2031
13.2.1. NSCLC
13.2.2. SCLC
13.3. Market Value Forecast, by Treatment Type, 2017–2031
13.3.1. Surgery
13.3.2. Radiation Therapy
13.3.3. Targeted Therapy
13.3.4. Immunotherapy
13.3.5. Chemotherapy
13.3.6. Others (palliative care)
13.4. Market Value Forecast, by End-user, 2017–2031
13.4.1. Hospitals
13.4.2. Cancer & Radiation Therapy Centers
13.4.3. Others (specialty clinics)
13.5. Market Value Forecast, by Country/Sub-region, 2017–2031
13.5.1. Brazil
13.5.2. Mexico
13.5.3. Rest of Latin America
13.6. Market Attractiveness Analysis
13.6.1. By Cancer Type
13.6.2. By Treatment Type
13.6.3. By End-user
13.6.4. By Country/Sub-region
14. Middle East & Africa Lung Cancer Treatment Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Cancer Type, 2017–2031
14.2.1. NSCLC
14.2.2. SCLC
14.3. Market Value Forecast, by Treatment Type, 2017–2031
14.3.1. Surgery
14.3.2. Radiation Therapy
14.3.3. Targeted Therapy
14.3.4. Immunotherapy
14.3.5. Chemotherapy
14.3.6. Others (palliative care)
14.4. Market Value Forecast, by End-user, 2017–2031
14.4.1. Hospitals
14.4.2. Cancer & Radiation Therapy Centers
14.4.3. Others (specialty clinics)
14.5. Market Value Forecast, by Country/Sub-region, 2017–2031
14.5.1. GCC Countries
14.5.2. South Africa
14.5.3. Rest of Middle East & Africa
14.6. Market Attractiveness Analysis
14.6.1. By Cancer Type
14.6.2. By Treatment Type
14.6.3. By End-user
14.6.4. By Country/Sub-region
15. Competition Landscape
15.1. Market Player - Competition Matrix (by tier and size of companies)
15.2. Market Share Analysis, by Company, 2021
15.3. Company Profiles
15.3.1. Pfizer
15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.1.2. Cancer Type Portfolio
15.3.1.3. Financial Overview
15.3.1.4. SWOT Analysis
15.3.1.5. Strategic Overview
15.3.2. AstraZeneca
15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.2.2. Cancer Type Portfolio
15.3.2.3. Financial Overview
15.3.2.4. SWOT Analysis
15.3.2.5. Strategic Overview
15.3.3. Merck (MSD)
15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.3.2. Cancer Type Portfolio
15.3.3.3. Financial Overview
15.3.3.4. SWOT Analysis
15.3.3.5. Strategic Overview
15.3.4. Bristol-Myers Squibb
15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.4.2. Cancer Type Portfolio
15.3.4.3. Financial Overview
15.3.4.4. SWOT Analysis
15.3.4.5. Strategic Overview
15.3.5. Eli Lilly and Company
15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.5.2. Cancer Type Portfolio
15.3.5.3. Financial Overview
15.3.5.4. SWOT Analysis
15.3.6. Boehringer Ingelheim
15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.6.2. Cancer Type Portfolio
15.3.6.3. Financial Overview
15.3.6.4. SWOT Analysis
15.3.7. Novartis
15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.7.2. Cancer Type Portfolio
15.3.7.3. Financial Overview
15.3.7.4. SWOT Analysis
15.3.8. Merck KGaA (EMD Serono)
15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.8.2. Cancer Type Portfolio
15.3.8.3. Financial Overview
15.3.8.4. SWOT Analysis
15.3.9. AbbVie
15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.9.2. Cancer Type Portfolio
15.3.9.3. Financial Overview
15.3.9.4. SWOT Analysis
15.3.10. Takeda
15.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.10.2. Cancer Type Portfolio
15.3.10.3. Financial Overview
15.3.10.4. SWOT Analysis
15.3.11. Astellas Pharma
15.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.11.2. Cancer Type Portfolio
15.3.11.3. Financial Overview
15.3.11.4. SWOT Analysis
15.3.12. F. Hoffmann-La Roche
15.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.12.2. Cancer Type Portfolio
15.3.12.3. Financial Overview
15.3.12.4. SWOT Analysis
15.3.13. GlaxoSmithKline
15.3.13.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.13.2. Cancer Type Portfolio
15.3.13.3. Financial Overview
15.3.13.4. SWOT Analysis
15.3.14. Johnson & Johnson
15.3.14.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.14.2. Cancer Type Portfolio
15.3.14.3. Financial Overview
15.3.14.4. SWOT Analysis
15.3.15. Sanofi
15.3.15.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.15.2. Cancer Type Portfolio
15.3.15.3. Financial Overview
15.3.15.4. SWOT Analysis
15.3.16. Amgen
15.3.16.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.16.2. Cancer Type Portfolio
15.3.16.3. Financial Overview
15.3.16.4. SWOT Analysis
List of Tables
Table 01: Global Lung Cancer Treatment Market Value (US$ Mn) Forecast, by Cancer Type, 2017–2031
Table 02: Global Lung Cancer Treatment Market Value (US$ Mn) Forecast, by Treatment Type, 2017–2031
Table 03: Global Lung Cancer Treatment Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 04: Global Lung Cancer Treatment Market Value (US$ Mn) Forecast, by Region, 2017–2031
Table 05: North America Lung Cancer Treatment Market Value (US$ Mn) Forecast, by Country, 2017–2031
Table 06: North America Lung Cancer Treatment Market Value (US$ Mn) Forecast, by Cancer Type, 2017–2031
Table 07: North America Lung Cancer Treatment Market Value (US$ Mn) Forecast, by Treatment Type, 2017–2031
Table 08: North America Lung Cancer Treatment Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 09: Europe Lung Cancer Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 10: Europe Lung Cancer Treatment Market Value (US$ Mn) Forecast, by Cancer Type, 2017–2031
Table 11: Europe Lung Cancer Treatment Market Value (US$ Mn) Forecast, by Treatment Type, 2017–2031
Table 12: Europe Lung Cancer Treatment Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 13: Asia Pacific Lung Cancer Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 14: Asia Pacific Lung Cancer Treatment Market Value (US$ Mn) Forecast, by Cancer Type, 2017–2031
Table 15: Asia Pacific Lung Cancer Treatment Market Value (US$ Mn) Forecast, by Treatment Type, 2017–2031
Table 16: Asia Pacific Lung Cancer Treatment Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 17: Latin America Lung Cancer Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 18: Latin America Lung Cancer Treatment Market Value (US$ Mn) Forecast, by Cancer Type, 2017–2031
Table 19: Latin America Lung Cancer Treatment Market Value (US$ Mn) Forecast, by Treatment Type, 2017–2031
Table 20: Latin America Lung Cancer Treatment Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 21: Middle East & Africa Lung Cancer Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 22: Middle East & Africa Lung Cancer Treatment Market Value (US$ Mn) Forecast, by Cancer Type, 2017–2031
Table 23: Middle East & Africa Lung Cancer Treatment Market Value (US$ Mn) Forecast, by Treatment Type, 2017–2031
Table 24: Middle East & Africa Lung Cancer Treatment Market Value (US$ Mn) Forecast, by End-user, 2017–2031
List of Figures
Figure 01: Global Lung Cancer Treatment Market Value (US$ Mn) Forecast, 2017–2031
Figure 02: Global Lung Cancer Treatment Market Value Share, by Cancer Type (2021)
Figure 03: Global Lung Cancer Treatment Market Value Share, by End-user (2021)
Figure 04: Global Lung Cancer Treatment Market Value Share, by Treatment Type (2021)
Figure 05: Global Lung Cancer Treatment Market Value Share, by Region (2021)
Figure 06: Global Lung Cancer Treatment Market Value Share Analysis, by Cancer Type, 2021 and 2031
Figure 07: Global Lung Cancer Treatment Market Revenue (US$ Mn), by NSCLC, 2017–2031
Figure 08: Global Lung Cancer Treatment Market Revenue (US$ Mn), by SCLC, 2017–2031
Figure 09: Global Lung Cancer Treatment Market Attractiveness Analysis, by Cancer Type, 2022–2031
Figure 10: Global Lung Cancer Treatment Market Value Share Analysis, by Treatment Type, 2021 and 2031
Figure 11: Global Lung Cancer Treatment Market Revenue (US$ Mn), by Surgery, 2017–2031
Figure 12: Global Lung Cancer Treatment Market Revenue (US$ Mn), by Radiation Therapy, 2017–2031
Figure 13: Global Lung Cancer Treatment Market Revenue (US$ Mn), by Others, 2017–2031
Figure 14: Global Lung Cancer Treatment Market Attractiveness Analysis, by Treatment Type, 2022–2031
Figure 15: Global Lung Cancer Treatment Market Value Share Analysis, by End-user, 2021 and 2031
Figure 16: Global Lung Cancer Treatment Market Revenue (US$ Mn), by Hospitals, 2017–2031
Figure 17: Global Lung Cancer Treatment Market Revenue (US$ Mn), by Cancer & Radiation Therapy Centers, 2017–2031
Figure 18: Global Lung Cancer Treatment Market Revenue (US$ Mn), by Others (specialty clinics), 2017–2031
Figure 19: Global Lung Cancer Treatment Market Attractiveness Analysis, by End-user, 2022–2031
Figure 20: Global Lung Cancer Treatment Market Value Share Analysis, by Region, 2021 and 2031
Figure 21: Global Lung Cancer Treatment Market Attractiveness Analysis, by Region, 2022-2031
Figure 22: North America Lung Cancer Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031
Figure 23: North America Lung Cancer Treatment Market Value Share (%), by Country, 2021 and 2031
Figure 24: North America Lung Cancer Treatment Market Attractiveness Analysis, by Country, 2022–2031
Figure 25: North America Lung Cancer Treatment Market Value Share Analysis, by Cancer Type, 2021 and 2031
Figure 26: North America Lung Cancer Treatment Market Attractiveness Analysis, by Cancer Type, 2022–2031
Figure 27: North America Lung Cancer Treatment Market Value Share Analysis, by Treatment Type, 2021 and 2031
Figure 28: North America Lung Cancer Treatment Market Attractiveness Analysis, by Treatment Type, 2022–2031
Figure 29: North America Lung Cancer Treatment Market Value Share Analysis, by End-user, 2021 and 2031
Figure 30: North America Lung Cancer Treatment Market Attractiveness Analysis, by End-user, 2022–2031
Figure 31: Europe Lung Cancer Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031
Figure 32: Europe Lung Cancer Treatment Market Value Share (%), by Country/Sub-region, 2021 and 2031
Figure 33: Europe Lung Cancer Treatment Market Attractiveness Analysis, by Country/Sub-region, 2022–2031
Figure 34: Europe Lung Cancer Treatment Market Value Share Analysis, by Cancer Type, 2021 and 2031
Figure 35: Europe Lung Cancer Treatment Market Attractiveness Analysis, by Cancer Type, 2022–2031
Figure 36: Europe Lung Cancer Treatment Market Value Share Analysis, by Treatment Type, 2021 and 2031
Figure 37: Europe Lung Cancer Treatment Market Attractiveness Analysis, by Treatment Type, 2022–2031
Figure 38: Europe Lung Cancer Treatment Market Value Share Analysis, by End-user, 2021 and 2031
Figure 39: Europe Lung Cancer Treatment Market Attractiveness Analysis, by End-user, 2022–2031
Figure 40: Asia Pacific Lung Cancer Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031
Figure 41: Asia Pacific Lung Cancer Treatment Market Value Share (%), by Country/Sub-region, 2021 and 2031
Figure 42: Asia Pacific Lung Cancer Treatment Market Attractiveness Analysis, by Country/Sub-region, 2022–2031
Figure 43: Asia Pacific Lung Cancer Treatment Market Value Share Analysis, by Cancer Type, 2021 and 2031
Figure 44: Asia Pacific Lung Cancer Treatment Market Attractiveness Analysis, by Cancer Type, 2022–2031
Figure 45: Asia Pacific Lung Cancer Treatment Market Value Share Analysis, by Treatment Type, 2021 and 2031
Figure 46: Asia Pacific Lung Cancer Treatment Market Attractiveness Analysis, by Treatment Type, 2022–2031
Figure 47: Asia Pacific Lung Cancer Treatment Market Value Share Analysis, by End-user, 2021 and 2031
Figure 48: Asia Pacific Lung Cancer Treatment Market Attractiveness Analysis, by End-user, 2022–2031
Figure 49: Latin America Lung Cancer Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031
Figure 50: Latin America Lung Cancer Treatment Market Value Share (%), by Country/Sub-region, 2021 and 2031
Figure 51: Latin America Lung Cancer Treatment Market Attractiveness Analysis, by Country/Sub-region, 2022–2031
Figure 52: Latin America Lung Cancer Treatment Market Value Share Analysis, by Cancer Type, 2021 and 2031
Figure 53: Latin America Lung Cancer Treatment Market Attractiveness Analysis, by Cancer Type, 2022–2031
Figure 54: Latin America Lung Cancer Treatment Market Value Share Analysis, by Treatment Type, 2021 and 2031
Figure 55: Latin America Lung Cancer Treatment Market Attractiveness Analysis, by Treatment Type, 2022–2031
Figure 56: Latin America Lung Cancer Treatment Market Value Share Analysis, by End-user, 2021 and 2031
Figure 57: Latin America Lung Cancer Treatment Market Attractiveness Analysis, by End-user, 2022–2031
Figure 58: Middle East & Africa Lung Cancer Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031
Figure 59: Middle East & Africa Lung Cancer Treatment Market Value Share (%), by Country/Sub-region, 2021 and 2031
Figure 60: Middle East & Africa Lung Cancer Treatment Market Attractiveness Analysis, by Country/Sub-region, 2022–2031
Figure 61: Middle East & Africa Lung Cancer Treatment Market Value Share Analysis, by Cancer Type, 2021 and 2031
Figure 62: Middle East & Africa Lung Cancer Treatment Market Attractiveness Analysis, by Cancer Type, 2022–2031
Figure 63: Middle East & Africa Lung Cancer Treatment Market Value Share Analysis, by Treatment Type, 2021 and 2031
Figure 64: Middle East & Africa Lung Cancer Treatment Market Attractiveness Analysis, by Treatment Type, 2022–2031
Figure 65: Middle East & Africa Lung Cancer Treatment Market Value Share Analysis, by End-user, 2021 and 2031
Figure 66: Middle East & Africa Lung Cancer Treatment Market Attractiveness Analysis, by End-user, 2022–2031
Figure 67: Global Lung Cancer Treatment Market Share Analysis, by Company, 2021
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Lung Cancer Treatment Market
